Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 4/20 | 0.76 |
| ▸ | HTR7 | P34969 | 2/20 | 0.76 |
| ▸ | HTR5A | P47898 | 2/20 | 0.76 |
| ▸ | MEN1 | O00255 | 6/20 | 0.75 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.75 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.75 |
| ▸ | MAPT | P10636 | 4/20 | 0.75 |
| ▸ | RECQL | P46063 | 3/20 | 0.75 |
| ▸ | USP2 | O75604 | 2/20 | 0.75 |
| ▸ | PLEC | Q15149 | 1/20 | 0.75 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.74 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.74 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.74 |
| ▸ | HPGD | P15428 | 3/20 | 0.74 |
| ▸ | DRD2 | P14416 | 3/20 | 0.74 |
| ▸ | HTR2A | P28223 | 3/20 | 0.74 |
| ▸ | HTR2C | P28335 | 3/20 | 0.74 |
| ▸ | DRD3 | P35462 | 3/20 | 0.74 |
| ▸ | HTR2B | P41595 | 3/20 | 0.74 |
| ▸ | LMNA | P02545 | 2/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13475442 | 1.00 | HTR6 (0.76) | HTR6HTR7HTR5AMEN1KMT2A | |
| SCHEMBL31079449 | 1.00 | HTR6 (0.76) | HTR6HTR7HTR5AMEN1KMT2A | |
| SCHEMBL26265120 | 0.90 | HSD17B10 (0.74) | HTR6HTR7HTR5AMEN1KMT2A | |
| SCHEMBL5425849 | 0.90 | HSD17B10 (0.74) | HTR6HTR7HTR5AMEN1KMT2A | |
| SCHEMBL26265117 | 0.90 | MEN1 (0.71) | HTR6HTR7HTR5AMEN1KMT2A | |
| SCHEMBL26265139 | 0.90 | HTR6 (0.81) | HTR6HTR7HTR5AMEN1KMT2A | |
| SCHEMBL26265097 | 0.90 | CXCR3 (0.69) | HTR6HTR7HTR5AMEN1KMT2A | |
| SCHEMBL30417228 | 0.89 | HTR6 (0.70) | HTR6HTR7HTR5AMEN1KMT2A | |
| SCHEMBL25545437 | 0.89 | MEN1 (0.79) | HTR6HTR7HTR5AMEN1KMT2A | |
| SCHEMBL25393584 | 0.89 | HTR6 (0.77) | HTR6HTR7HTR5AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4499109-A1 | PSYCHEDELIC COMPOSITIONS AND METHODS FOR FORMING THE SAME | Ojai Energetics PBC (US) | 2025-02-05 | — | — | EP | claimed |
| US-20230405028-A1 | COMPOSITIONS FOR REDUCING INFLAMMATION TO IMPROVE OR MAINTAIN MENTAL OR PHYSICAL HEALTH | GOODCAP PHARMACEUTICALS LTD (CA) | 2023-12-21 | — | — | US | claimed |
| WO-2023183618-A1 | PSYCHEDELIC COMPOSITIONS AND METHODS FOR FORMING THE SAME | OJAI ENERGETICS PBC (US) | 2023-09-28 | — | — | WO | claimed |
| EP-4225320-A1 | COMPOSITIONS FOR REDUCING INFLAMMATION TO IMPROVE OR MAINTAIN MENTAL OR PHYSICAL HEALTH | Goodcap Pharmaceuticals Ltd. (CA) | 2023-08-16 | — | — | EP | claimed |
| WO-2022079574-A1 | COMPOSITIONS FOR REDUCING INFLAMMATION TO IMPROVE OR MAINTAIN MENTAL OR PHYSICAL HEALTH | GOODCAP PHARMACEUTICALS LTD. (CA) | 2022-04-21 | — | — | WO | claimed |
| US-20260108493-A1 | COMPOSITIONS COMPRISING A SEROTONERGIC TRYPTAMINE COMPOUND | CAAMTECH, INC. (US) | 2026-04-23 | — | — | US | disclosed |
| US-20260092034-A1 | 7-AZAINDOLE ANALOGS AND METHODS OF TREATING NEUROLOGICAL DISORDERS USING THE SAME | KULEON LLC (US) | 2026-04-02 | — | — | US | disclosed |
| EP-4704846-A2 | NOVEL ERGOLINES AND METHODS OF TREATING MOOD DISORDERS | Gilgamesh Pharmaceuticals, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| US-12570602-B2 | Selective serotonin receptor modulators and methods of making and using the same | Park City Bio, LLC (US) | 2026-03-10 | — | — | US | disclosed |
| US-12564560-B1 | Selective serotonin receptor modulators and methods of making and using the same | Park City Bio, LLC (US) | 2026-03-03 | — | — | US | disclosed |
| US-20250376436-A1 | Selective Serotonin Receptor Modulators and Methods of Making and Using the Same | Park City Bio, LLC (US) | 2025-12-11 | — | — | US | disclosed |
| US-20250340513-A1 | NEUROPLASTOGENS AND NON-HALLUCINOGENIC SEROTONIN 5-HT2A/2C RECEPTOR MODULATORS | KULEON LLC (US) | 2025-11-06 | — | — | US | disclosed |
| US-20130023045-A1 | INDUCED HEPATIC STEM CELL AND PROCESS FOR PRODUCTION THEREOF, AND APPLICATIONS OF THE CELL | NATIONAL CANCER CENTER (JP) | 2013-01-24 | — | — | US | disclosed |
| EP-2532741-A1 | INDUCED HEPATIC STEM CELL AND PROCESS FOR PRODUCTION THEREOF, AND APPLICATIONS OF THE CELL | National Cancer Center Research Institute (JP) | 2012-12-12 | — | — | EP | disclosed |
| US-20120156179-A1 | METHOD FOR INDUCING EXTENDED SELF-RENEWAL OF FUNCTIONALLY DIFFERENTIATED SOMATIC CELLS | UNIVERSITE DE LA MEDITERRANEE (AIX-MARSEILLE II) (FR) | 2012-06-21 | — | — | US | disclosed |
| US-20120156179-A1 | METHOD FOR INDUCING EXTENDED SELF-RENEWAL OF FUNCTIONALLY DIFFERENTIATED SOMATIC CELLS | UNIVERSITE DE LA MEDITERRANEE (AIX-MARSEILLE II) (FR) | 2012-06-21 | — | — | US | disclosed |
| US-20120156179-A1 | METHOD FOR INDUCING EXTENDED SELF-RENEWAL OF FUNCTIONALLY DIFFERENTIATED SOMATIC CELLS | UNIVERSITE DE LA MEDITERRANEE (AIX-MARSEILLE II) (FR) | 2012-06-21 | — | — | US | disclosed |
| EP-2451836-A1 | A METHOD FOR INDUCING EXTENDED SELF-RENEWAL OF FUNCTIONALLY DIFFERENTIATED SOMATIC CELLS | INSERM - Institut National de la Santé et de la Recherche Médicale (FR) | 2012-05-16 | — | — | EP | disclosed |
| WO-2012022725-A2 | CONVERSION OF SOMATIC CELLS TO INDUCED REPROGRAMMED NEURAL STEM CELLS (IRNSCS) | F. HOFFMANN-LA ROCHE AG (CH) | 2012-02-23 | — | — | WO | disclosed |
| WO-2011003988-A1 | A METHOD FOR INDUCING EXTENDED SELF-RENEWAL OF FUNCTIONALLY DIFFERENTIATED SOMATIC CELLS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2011-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250376436-A1 | Selective Serotonin Receptor Modulators and Methods of Making and Using the Same | HTR1A, HTR4, HTR5A | HTR6 9/4885HTR7 5/4885HTR5A 3/4885 |
| US-20260092034-A1 | 7-AZAINDOLE ANALOGS AND METHODS OF TREATING NEUROLOGICAL DISORDERS USING THE SAME | HTR2C, HTR7, HTR6 | HTR6 3/4885HTR7 2/4885HTR5A 13/4885 |
| US-20120156179-A1 | METHOD FOR INDUCING EXTENDED SELF-RENEWAL OF FUNCTIONALLY DIFFERENTIATED SOMATIC CELLS | MYCBP, MYC, KIF5B | HTR6 4537/4885HTR7 4611/4885HTR5A 4552/4885 |
| US-20260108493-A1 | COMPOSITIONS COMPRISING A SEROTONERGIC TRYPTAMINE COMPOUND | ADRA2C, ADRB3, ADRA2B | HTR6 16/4885HTR7 35/4885HTR5A 13/4885 |
| US-20250340513-A1 | NEUROPLASTOGENS AND NON-HALLUCINOGENIC SEROTONIN 5-HT2A/2C RECEPTOR MODULATORS | HTR2A, HTR2C, HTR3A | HTR6 9/4885HTR7 14/4885HTR5A 11/4885 |
| US-12570602-B2 | Selective serotonin receptor modulators and methods of making and using the same | HTR1D, HTR1A, HTR4 | HTR6 8/4885HTR7 13/4885HTR5A 4/4885 |
| US-12564560-B1 | Selective serotonin receptor modulators and methods of making and using the same | HTR5A, HTR1A, HTR1D | HTR6 9/4885HTR7 13/4885HTR5A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.